All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

  TRANSLATE

The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

How can MRD kinetics assessment help with treatment decisions during maintenance therapy?

Featured:

Bruno PaivaBruno Paiva

Jun 30, 2021


Video series

During the EHA2021 Virtual Congress, the Multiple Myeloma Hub spoke with Bruno Paiva, University of Navarra, Pamplona, ES. We asked, How can measurable residual disease (MRD) kinetics assessment help with treatment decisions during maintenance therapy?

In this video, Paiva discusses the role of assessing MRD kinetics data in optimizing treatment management in the maintenance setting.